Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD25 rhMAb in Steroid-Refractory cGVHD of the Liver
NCT06364319Phase 4Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Jul 2026
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
01
Overview
Phase 4, open-label, single-arm trial of daclizumab in chronic graft-versus-host disease (cGVHD), sponsored by Peking University People's Hospital. Primary endpoint: Overall Response Rate at 56 days. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
daclizumab
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT06364319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06364319.